IMU has multiple products all with a massive market and like all biotech start-up stocks, the pps will rise as further positive clinical updates are released for their multiple trials. This is dejavu on the RAP thread when others non holders tried to get us buying PCK and RSH and I told them, all about the technology's market and whether they have any limitation which will affect the commercialisation success. Guess what? I didn't invest in either PCK and RSH which turn out to be the correct decision lol
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)